Merck’s newly FDA-approved Lipfendra delivers the powerful cholesterol-lowering effects of a PCSK9 inhibitor in a once-daily pill. The drug reduced LDL by 56% to 60% in Phase 3 trials.

Alirocumab plus statin slowed coronary calcium progression: +2.9% vs +10.6% at 18 months
Summarises a 2022 RCT in CAD patients on moderate statins: alirocumab 75 mg every 2 weeks for 18 months limited CAC progression, with Lp(a) change correlating with CAC change. A retrospective study (Ikegami) found about half the annual CAC progression with PCSK9 inhibitor plus statin; studies are small and larger trials are needed.


